Featured Content

  • Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses.
  • Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corp.? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview with The Life Sciences Report.
  • Enanta Pharmaceutical's review slated for late December Enanta Pharmaceutical, Inc, (NASDAQ:ENTA) recently announced that their collaborator Abbvie’s New Drug Application for an interferon-free regimen had been acknowledged by U.S. Food and Drug Administration. The NDA for acceptance of this regimen was submitted on April 21, 2014. The BioMedReports FDA Calendar shows a date for review on December 21, 2014.
  • Pozen’s PA8140/PA32540 Tablets Get Another Look As you may know, POZEN Inc. (NASDAQ: POZN), gets another chance for a New Drug Application reevaluation after their previous NDA was not accepted due to the issues indicated at some stage in an inspection of the production facility creating an essential constituent necessary for the production of the firm's PA8140/PA32540 Tablets.
  • Closer Look: Cubist Pharmaceuticals' New Antibiotic Contender Cubist Pharmaceuticals (NASDAQ:CBST) previously announced that new antibiotic Ceftolozane has a new drug application which is being out through the steps by the Food and Drug Administration under a priority review, moreover, the FDA has issued a drug user fee act (PDUFA) date of December 21, 2014.
More News

News and Analysis

More News

Sector News

More News

Subscriber Only Content

More News


BioMedReports OncoMed Offers Data from Demcizumab; Celgene Receives Positive CHMP Opinion For OTEZLA: Below is a look at som... http://t.co/ZkvEC7x99Y
BioMedReports Soaring generic drug prices draw Senate scrutiny... http://t.co/Fzq7h0GODI
BioMedReports Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial; Marina and Mirna Amend License A... http://t.co/l3kFbpKB92
Benzinga.com supporter Seeking Alpha Certified

RSS Subscription